superpotent

superpotent

(soo″pĕr-pōt′ĕnt) [ super- + potent]
Exceptionally strong; characteristic of certain medications.
References in periodicals archive ?
There was very little use of superpotent topical steroids, topical calcineurin inhibitors, or immunosuppressants, although 10% of pregnant women received systemic corticosteroids for their AD.
might have to change as superpotent drugs like fentanyl, the synthetic
According to the companies, BRYHALI (halobetasol propionate) Lotion, 0.01% is a new potent to superpotent corticosteroid that contains 0.01% halobetasol propionate in a novel vehicle lotion.
BRYHALI Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate in a novel vehicle lotion.
Other interesting associations were detected between MCC and Langerhans cell sarcoma tissues [40] and during treatment with superpotent topical steroids and methotrexate for bullous pemphigoid [41].
The type and potency of topical steroid used by patients varied from low-mid potency (45%) followed by mid potency (25%) and superpotent corticosteroids (30%).
In our study, potencies of the topical corticosteroids that were prescribed were commonly of superpotent (59.7%) and potent (26.1%), which were comparable to studies done by Jena et al.
Patient 1 was treated with superpotent topical corticosteroids prior to presentation to our department.
It was shown in some studies that using potent and superpotent steroids provides 75% repigmentation in approximately 60% of the patients (16, 17).
* In our patient's case, the vaso-occlusive properties of topical steroids explain why the superpotent steroid (clobetasol) he was prescribed increased his pain and worsened the underlying problem.
Number of patients (%) P * Various classes Class I (superpotent) 4(1) Class II (potent) 96 (25) Class III (least potent) 23 (6) Handcrafted cosmetic containing TC 261 (68) Duration use 3 weeks-3 months 41 (10,6) 3 months-11 months 50 (13) 1-5 years 184 (48) <0,05 * 6-10 years 47 (12,2) >10 years 62 (16,1) * Common duration use of TC is between 1 and 5 years.
While the risk of mortality from GVHD increases when immunosuppressants are not potent enough, superpotent immunosuppressants increase the risks of recurrent leukemia and infection.